蜇伤通过 PARP-1/NLRP3 信号通路参与加重败血症急性肺损伤的过程

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pulmonary pharmacology & therapeutics Pub Date : 2024-06-05 DOI:10.1016/j.pupt.2024.102303
Tingting Ying , Yulong Yu , Qimin Yu, Gang Zhou, Lingyang Chen, Yixiao Gu, Lijun Zhu, Haifeng Ying, Minjuan Chen
{"title":"蜇伤通过 PARP-1/NLRP3 信号通路参与加重败血症急性肺损伤的过程","authors":"Tingting Ying ,&nbsp;Yulong Yu ,&nbsp;Qimin Yu,&nbsp;Gang Zhou,&nbsp;Lingyang Chen,&nbsp;Yixiao Gu,&nbsp;Lijun Zhu,&nbsp;Haifeng Ying,&nbsp;Minjuan Chen","doi":"10.1016/j.pupt.2024.102303","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Interferon gene stimulator (Sting) is an indispensable adaptor protein that plays a crucial role in acute lung injury (ALI) induced by sepsis, and the PARP-1/NLRP3 signaling pathway may be an integral component of the inflammatory response mediated by Sting. However, the regulatory role of Sting in the PARP-1/NLRP3 pathway in ALI remains insufficiently elucidated.</p></div><div><h3>Methods</h3><p>Using lipopolysaccharide (LPS) to induce ALI in C57BL/6 mice and HUVEC cells, an <em>in vivo</em> and <em>in vitro</em> model was established. <em>In vivo</em>, Sting agonists and inhibitors were administered, while <em>in vitro</em>, Sting was knocked down using siRNA. ELISA was employed to quantify the levels of IL-1β, IL-6, and TNF-α. TUNEL staining was conducted to assess cellular apoptosis, while co-immunoprecipitation was utilized to investigate the interaction between Sting and NLRP3. Expression levels of Sting, NLRP3, PARP-1, among others, were assessed via Western blotting and RT-qPCR. Lung HE staining and lung wet/dry ratio were evaluated in the <em>in vivo</em> mouse model. To validate the role of the PARP-1/NLRP3 signaling pathway, PARP-1 inhibitors were employed both <em>in vivo</em> and <em>in vitro</em>.</p></div><div><h3>Results</h3><p><em>In vitro</em> experiments revealed that the Sting agonist group exacerbated LPS-induced pulmonary pathological damage, pulmonary edema, inflammatory response (increased levels of IL-6, TNF-α, and IL-1β), and cellular injury, whereas the Sting inhibitor group significantly ameliorated the aforementioned injuries, with further improvement observed in the combination therapy of Sting inhibitor and PARP-1 inhibitor. Western blotting and RT-qPCR results demonstrated significant suppression of ICAM-1, VCAM-1, NLRP3, and PARP-1 expression in the Sting inhibitor group, with this reduction further enhanced in the Sting inhibitor + PARP-1 inhibitor treatment group, exhibiting opposite outcomes to the agonist. Furthermore, <em>in vitro</em> experiments using HUVEC cell lines validated these findings.</p></div><div><h3>Conclusions</h3><p>Our study provides new insights into the roles of Sting and the PARP-1/NLRP3 signaling pathway in inflammatory responses, offering novel targets for the development of therapeutic interventions against inflammatory reactions.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"86 ","pages":"Article 102303"},"PeriodicalIF":3.3000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The involvement of Sting in exacerbating acute lung injury in sepsis via the PARP-1/NLRP3 signaling pathway\",\"authors\":\"Tingting Ying ,&nbsp;Yulong Yu ,&nbsp;Qimin Yu,&nbsp;Gang Zhou,&nbsp;Lingyang Chen,&nbsp;Yixiao Gu,&nbsp;Lijun Zhu,&nbsp;Haifeng Ying,&nbsp;Minjuan Chen\",\"doi\":\"10.1016/j.pupt.2024.102303\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Interferon gene stimulator (Sting) is an indispensable adaptor protein that plays a crucial role in acute lung injury (ALI) induced by sepsis, and the PARP-1/NLRP3 signaling pathway may be an integral component of the inflammatory response mediated by Sting. However, the regulatory role of Sting in the PARP-1/NLRP3 pathway in ALI remains insufficiently elucidated.</p></div><div><h3>Methods</h3><p>Using lipopolysaccharide (LPS) to induce ALI in C57BL/6 mice and HUVEC cells, an <em>in vivo</em> and <em>in vitro</em> model was established. <em>In vivo</em>, Sting agonists and inhibitors were administered, while <em>in vitro</em>, Sting was knocked down using siRNA. ELISA was employed to quantify the levels of IL-1β, IL-6, and TNF-α. TUNEL staining was conducted to assess cellular apoptosis, while co-immunoprecipitation was utilized to investigate the interaction between Sting and NLRP3. Expression levels of Sting, NLRP3, PARP-1, among others, were assessed via Western blotting and RT-qPCR. Lung HE staining and lung wet/dry ratio were evaluated in the <em>in vivo</em> mouse model. To validate the role of the PARP-1/NLRP3 signaling pathway, PARP-1 inhibitors were employed both <em>in vivo</em> and <em>in vitro</em>.</p></div><div><h3>Results</h3><p><em>In vitro</em> experiments revealed that the Sting agonist group exacerbated LPS-induced pulmonary pathological damage, pulmonary edema, inflammatory response (increased levels of IL-6, TNF-α, and IL-1β), and cellular injury, whereas the Sting inhibitor group significantly ameliorated the aforementioned injuries, with further improvement observed in the combination therapy of Sting inhibitor and PARP-1 inhibitor. Western blotting and RT-qPCR results demonstrated significant suppression of ICAM-1, VCAM-1, NLRP3, and PARP-1 expression in the Sting inhibitor group, with this reduction further enhanced in the Sting inhibitor + PARP-1 inhibitor treatment group, exhibiting opposite outcomes to the agonist. Furthermore, <em>in vitro</em> experiments using HUVEC cell lines validated these findings.</p></div><div><h3>Conclusions</h3><p>Our study provides new insights into the roles of Sting and the PARP-1/NLRP3 signaling pathway in inflammatory responses, offering novel targets for the development of therapeutic interventions against inflammatory reactions.</p></div>\",\"PeriodicalId\":20799,\"journal\":{\"name\":\"Pulmonary pharmacology & therapeutics\",\"volume\":\"86 \",\"pages\":\"Article 102303\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pulmonary pharmacology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1094553924000191\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary pharmacology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094553924000191","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:干扰素基因刺激因子(Sting)是一种不可或缺的适配蛋白,在脓毒症诱发的急性肺损伤(ALI)中发挥着至关重要的作用,而PARP-1/NLRP3信号通路可能是Sting介导的炎症反应中不可或缺的组成部分。然而,Sting在ALI中PARP-1/NLRP3通路的调控作用仍未得到充分阐明:方法:利用脂多糖(LPS)诱导 C57BL/6 小鼠和 HUVEC 细胞的 ALI,建立了体内和体外模型。在体内,使用Sting激动剂和抑制剂;在体外,使用siRNA敲除Sting。采用酶联免疫吸附试验量化 IL-1β、IL-6 和 TNF-α 的水平。TUNEL染色用于评估细胞凋亡,共免疫沉淀用于研究Sting和NLRP3之间的相互作用。通过 Western 印迹和 RT-qPCR 评估了 Sting、NLRP3、PARP-1 等的表达水平。在体内小鼠模型中评估了肺HE染色和肺干湿比。为了验证 PARP-1/NLRP3 信号通路的作用,在体内和体外都使用了 PARP-1 抑制剂:体外实验结果显示,Sting激动剂组加重了LPS诱导的肺病理损伤、肺水肿、炎症反应(IL-6、TNF-α和IL-1β水平升高)和细胞损伤,而Sting抑制剂组则明显改善了上述损伤,Sting抑制剂和PARP-1抑制剂联合治疗后,上述损伤得到进一步改善。Western 印迹和 RT-qPCR 结果表明,Sting 抑制剂组能显著抑制 ICAM-1、VCAM-1、NLRP3 和 PARP-1 的表达,而在 Sting 抑制剂 + PARP-1 抑制剂治疗组中,这种抑制作用进一步增强,表现出与激动剂相反的结果。此外,使用 HUVEC 细胞系进行的体外实验也验证了这些发现:我们的研究为了解 Sting 和 PARP-1/NLRP3 信号通路在炎症反应中的作用提供了新的视角,为开发针对炎症反应的治疗干预措施提供了新的靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The involvement of Sting in exacerbating acute lung injury in sepsis via the PARP-1/NLRP3 signaling pathway

Background

Interferon gene stimulator (Sting) is an indispensable adaptor protein that plays a crucial role in acute lung injury (ALI) induced by sepsis, and the PARP-1/NLRP3 signaling pathway may be an integral component of the inflammatory response mediated by Sting. However, the regulatory role of Sting in the PARP-1/NLRP3 pathway in ALI remains insufficiently elucidated.

Methods

Using lipopolysaccharide (LPS) to induce ALI in C57BL/6 mice and HUVEC cells, an in vivo and in vitro model was established. In vivo, Sting agonists and inhibitors were administered, while in vitro, Sting was knocked down using siRNA. ELISA was employed to quantify the levels of IL-1β, IL-6, and TNF-α. TUNEL staining was conducted to assess cellular apoptosis, while co-immunoprecipitation was utilized to investigate the interaction between Sting and NLRP3. Expression levels of Sting, NLRP3, PARP-1, among others, were assessed via Western blotting and RT-qPCR. Lung HE staining and lung wet/dry ratio were evaluated in the in vivo mouse model. To validate the role of the PARP-1/NLRP3 signaling pathway, PARP-1 inhibitors were employed both in vivo and in vitro.

Results

In vitro experiments revealed that the Sting agonist group exacerbated LPS-induced pulmonary pathological damage, pulmonary edema, inflammatory response (increased levels of IL-6, TNF-α, and IL-1β), and cellular injury, whereas the Sting inhibitor group significantly ameliorated the aforementioned injuries, with further improvement observed in the combination therapy of Sting inhibitor and PARP-1 inhibitor. Western blotting and RT-qPCR results demonstrated significant suppression of ICAM-1, VCAM-1, NLRP3, and PARP-1 expression in the Sting inhibitor group, with this reduction further enhanced in the Sting inhibitor + PARP-1 inhibitor treatment group, exhibiting opposite outcomes to the agonist. Furthermore, in vitro experiments using HUVEC cell lines validated these findings.

Conclusions

Our study provides new insights into the roles of Sting and the PARP-1/NLRP3 signaling pathway in inflammatory responses, offering novel targets for the development of therapeutic interventions against inflammatory reactions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
41
审稿时长
42 days
期刊介绍: Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews. Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology.
期刊最新文献
Triple inhaled therapy in asthma: beliefs, behaviours and doubts. Prevalence and clinical significance of pre- and post-bronchodilator airflow obstruction in COPD patients Hyperbaric oxygen therapy as an immunomodulatory intervention in COVID-19-induced ARDS: Exploring clinical outcomes and transcriptomic signatures in a randomised controlled trial Interaction between fluticasone furoate and umeclidinium in passively sensitized isolated human airways Chest CT assess the impact of omalizumab treatment on airway remodeling in refractory asthma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1